Medicinal Products

PEFLACINE 400 mg 400 mg / 5 mL

Generic drug of the therapeutic class: Infectiology - Parasitology
Active ingredients: Pefloxacin
laboratory: Sanofi-Aventis France

Injection solution for IV infusion
Box of 5 ampoules of 5 ml
All forms


PEFLACINE 400 mg IV infusion solution for infusion is indicated in adults for the treatment of the following infections (see sections Warnings and Precautions and Pharmacodynamic Properties ). Special attention should be paid to the available information on bacterial resistance to pefloxacin before initiating treatment.

Official recommendations concerning the appropriate use of antibacterials should be taken into account.

In the adult

Severe infections caused by gram-negative bacilli and susceptible staphylococci in their manifestations:

o septicemic and endocardial

o meningeal,

o respiratory,

o otolaryngology,

o urinary,

o the genital tract,

o abdominal and hepatobiliary,

o osteo-articular,

o cutaneous.

During the treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections, the emergence of resistant mutants has been described and may warrant the combination of another antibiotic. Microbiological monitoring in search of such resistance should be considered, particularly in case of suspicion of failure.

Dosage PEFLACINE 400 mg 400 mg / 5 mL Solution for IV infusion Pack of 5 5 ml ampoules



In the subject with normal liver functions

800 mg per day on average in two daily infusions, one in the morning and one in the evening.
To achieve effective blood levels faster, a loading dose of 800 mg can be indicated at the first dose.

In patients with hepatic insufficiency

In subjects with severe hepatic impairment or decreased hepatic blood flow, the daily dose should be adjusted by decreasing the rate of administration, ie 8 mg / kg infused within one hour:

· 2 times daily if there is no jaundice or ascites,

· Once a day in case of jaundice,

· Every 36 hours in case of ascites,

· Every 2 days if there is ascites and jaundice.

(see section Warnings and precautions for use ).

In the elderly

In subjects over 65 years of age: 400 mg daily in two 200 mg infusions, 12 hours apart (see Warnings and Precautions ) section.

Pediatric population

PEFLACIN 400 mg IV solution for infusion is contraindicated in children and adolescents until the end of the growth period (see section 4.3 ).

Administration mode

Injectable way.

This drug should be administered as a slow intravenous infusion (one hour) after addition of the 400 mg ampoule in 125 ml or 250 ml of 5 g per 100 glucose solution for injection.

Against indications

This medicine should never be used:

· In children or adolescents during growth (because of the risk of severe arthropathies affecting electively large joints),

· In patients with hypersensitivity to pefloxacin, other quinolones or to any of the components of this drug (see section Composition ),

· In patients with a history of quinolone-related tendinopathy (see sections Warnings and Precautions and Adverse Reactions ),

· In breastfeeding women (see section Pregnancy and breastfeeding ).

Side effects Peflacin 400 MG

Data on the frequency of adverse events are from clinical trials (including literature). The most common side effects with pefloxacin are insomnia, gastralgia, nausea, vomiting, urticaria, arthralgia and myalgia. The most serious side effects include: pancytopenia, anaphylactic shock, seizures, Stevens-Johnson syndrome, Lyell's syndrome, aggravation of myasthenia gravis, tendon ruptures and acute renal failure.

Class of organ systems


(≥ 1/100 to



(≥ 1/1 000 to



(≥ 1/10 000 to


Very rare

(<1 / 10, 000)

Not known (can not be estimated from the available data)

Blood and lymphatic system disorders






Immune system disorders


Anaphylactic shock (see section Warnings and precautions for use )

Nervous system disorders








Seizures (see section Warnings and Precautions for Use ),


Intracranial hypertension (particularly in young subjects, after prolonged treatment with pefloxacin, the evolution being favorable in most cases after stopping treatment with pefloxacin and setting up appropriate treatment),




Peripheral neuropathies

sensitive or sensitivomotor (see section Warnings and Precautions for Use ),

Aggravation of myasthenia gravis (see section Warnings and precautions for use )

Gastrointestinal disorders





Colity pseudo

membranous (see section Warnings and precautions for use )

Hepatobiliary disorders

Elevation of transaminases,

alkaline phosphatases,

Increased blood bilirubin

Skin and subcutaneous tissue disorders



sensitivity (see section Warnings and precautions for use )



Vascular purpura,



Stevens-Johnson Syndrome,

Lyell Syndrome

Musculoskeletal and connective tissue disorders and bone disorders




Tendon rupture (possibility of slow healing or sequelae for tendon disorders) (see sections Contraindications and Warnings and precautions for use ),

Joint effusion

Renal and urinary disorders

Acute renal failure

Popular Posts

Category Medicinal Products, Next Article